Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
February 07, 2024 17:01 ET
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology...
Mydecine Innovations Group Announces Director Resignation
February 02, 2024 16:05 ET
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology...
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
December 18, 2023 02:00 ET
|
Mydecine Innovations Group Inc.
MYCO announces it has received the issuance of a Notice of Allowance by the United States Patent and Trademark Office for MYCO-005 compound
Mydecine Announces Update Regarding the Special Access Program
November 28, 2023 16:05 ET
|
Mydecine Innovations Group Inc.
DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of...
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
October 31, 2023 02:00 ET
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company...
Mydecine Provides Q4 2023 Business Update
October 26, 2023 02:00 ET
|
Mydecine Innovations Group Inc.
Mydecine is pleased to address its shareholders and provide a general update on the company's progress.
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK
October 12, 2023 02:00 ET
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NFA), a biotechnology...
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings
October 10, 2023 02:00 ET
|
Mydecine Innovations Group Inc.
The Company has completed its admission to the Access segment of the AQSE Growth Market and trading will commence at 8:00 A.M. GM - Oct 10, 2023 - "MYIG"
Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
October 05, 2023 17:01 ET
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the...
Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
September 27, 2023 17:18 ET
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering...